Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of KD-414 in pediatric patients

Next Previous
Search
Trial Profile

A phase III study of KD-414 in pediatric patients

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 vaccine (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Meiji Holdings

    • Most Recent Events

    • 07 Feb 2023 New trial record
    • 31 Jan 2023 According to Meiji media release, the company is partially funded by the Ministry of Health, Labour and Welfare of Japan and by research grants from the Japan Agency for Medical Research and Development (AMED) for this study along with ongoing clinical trials and construction of manufacturing facilities for KD-414.
    • 31 Jan 2023 According to Meiji media release, the company has initiated this study and the first patient has been dosed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top